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Abstract
Background: Acute lymphoblastic leukemia (ALL) is the most common pediatric cancer. While the multi-step model of
pediatric leukemogenesis suggests interplay between constitutional and somatic genomes, the role of inherited genetic
variability remains largely undescribed. Nonsyndromic familial ALL, although extremely rare, provides the ideal setting to
study inherited contributions to ALL. Toward this goal, we sequenced the exomes of a childhood ALL family consisting of
mother, father and two non-twinned siblings diagnosed with concordant pre-B hyperdiploid ALL and previously shown
to have inherited a rare form of PRDM9, a histone H3 methyltransferase involved in crossing-over at recombination
hotspots and Holliday junctions. We postulated that inheritance of additional rare disadvantaging variants in predisposing
cancer genes could affect genomic stability and lead to increased risk of hyperdiploid ALL within this family.
Methods: Whole exomes were captured using Agilent’s SureSelect kit and sequenced on the Life Technologies SOLiD
System. We applied a data reduction strategy to identify candidate variants shared by both affected siblings. Under a
recessive disease model, we focused on rare non-synonymous or frame-shift variants in leukemia predisposing pathways.
Results: Though the family was nonsyndromic, we identified a combination of rare variants in Fanconi anemia (FA) genes
FANCP/SLX4 (compound heterozygote - rs137976282/rs79842542) and FANCA (rs61753269) and a rare homozygous
variant in the Holliday junction resolvase GEN1 (rs16981869). These variants, predicted to affect protein function, were
previously identified in familial breast cancer cases. Based on our in-house database of 369 childhood ALL exomes, the
sibs were the only patients to carry this particularly rare combination and only a single hyperdiploid patient was
heterozygote at both FANCP/SLX4 positions, while no FANCA variant allele carriers were identified. FANCA is the most
commonly mutated gene in FA and is essential for resolving DNA interstrand cross-links during replication. FANCP/SLX4
and GEN1 are involved in the cleavage of Holliday junctions and their mutated forms, in combination with the rare allele
of PRDM9, could alter Holliday junction resolution leading to nondisjunction of chromosomes and segregation defects.
Conclusion: Taken together, these results suggest that concomitant inheritance of rare variants in FANCA, FANCP/SLX4
and GEN1 on the specific genetic background of this familial case, could lead to increased genomic instability,
hematopoietic dysfunction, and higher risk of childhood leukemia.
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Background
ALL accounts for approximately 25 % of all pediatric can-
cer cases, however its etiology remains elusive [1]. Direct
evidence that childhood ALL has a genetic component is
provided by the high risk of developing the disease associ-
ated with certain inherited cancer-predisposing syndromes
such as Bloom’s syndrome, Down syndrome, Fanconi
anemia, neurofibromatosis and ataxia telangiectasia,
however they account for a trivial proportion of cases
(collectively <5 %) [2]. A heritable basis for ALL outside
these syndromes is largely undefined. Genome-wide associ-
ation studies provided the first unambiguous evidence that
common inherited genetic variation increases the risk of
developing childhood ALL [3–6]. The identification of
low-penetrance susceptibility alleles at 7p12.2 (IKZF1),
9p12 (CDKN2A/CDKN2B), 10q21.2 (ARID5B) and
14q11.2 (CEBPE) in genes involved in transcriptional
regulation and differentiation of B-lymphocyte pro-
genitors, highlights the role of constitutional genetic
predisposition in childhood ALL onset. Yet these loci only
explain a small proportion of the familial risk associated
with childhood ALL [7] suggesting that the underlying
genetic architecture likely involves co-inheritance of mul-
tiple variants on a wide allelic spectrum with varying
penetrance. While large population-based cohorts will be
required to identify additional common ALL-predisposing
variants, families with multiple non-twinned ALL sibships,
though extremely rare [8, 9], represent ideal models to in-
vestigate the role of rare/private inherited genetic vari-
ation in disease etiology.
Through a recent international collaborative effort to
identify childhood ALL families, it was reported that ALL
sibs exhibit high subtype concordance, likely explained by
shared underlying genetic risk [8]. Here we report the case
of a nonsyndromic pre-B childhood ALL family with two
male non-twinned siblings diagnosed with hyperdiploid
pre-B ALL. The prenatal origins of hyperdiploid childhood
ALL and the need for additional postnatal mutations to
drive overt leukemogenesis are well established [10]. The
extent to which inherited genetic variation contributes to
the onset of hyperdiploid childhood ALL however is less
clear. The sibs were previously shown to have maternally
inherited a rare allelic form of PRDM9, a meiosis-specific
histone H3 methyltransferase that was suggested to influ-
ence genomic instability in ALL by potentially controlling
the location of genetic crossing-over at recombination
hotspots [11] and at Holliday junctions [12]. Based on
these data, we postulated that co-inheritance of additional
rare disadvantaging DNA variants is likely required to ex-
plain this familial case of ALL, the identification of which
could allow for better understanding of leukemogenesis
and benefit a much broader childhood ALL population.
Even though the family was otherwise asymptomatic, be-
cause the Fanconi anemia (FA) pathway is a well-known
leukemia predisposing disorder and FA-associated gene
dysfunction has been linked to genomic instabilities, defects
in Holliday junction resolution [13] and aneuploidy
[14], we postulated that inherited rare disadvantaging
DNA variants in FA cancer predisposing genes/path-
way, in combination with PRDM9, could contribute to
the chromosome instabilities underlying this case of fa-
milial hyperdiploid childhood ALL.
Methods
Patients
This nonsyndromic pre-B childhood ALL family is of self-
reported Moroccan origin (Fig. 1); three unaffected sibs
(two females and one male) could not be ascertained.
Family history includes death due to cancer of both mater-
nal and paternal grandfathers, colon cancer at age 69 and
prostate cancer at age 65, respectively. A consanguineous
marriage (first cousins) on the paternal side lead to mul-
tiple miscarriages and children with polymalformation
syndrome, one of which died at 1 week. The probands
were diagnosed with childhood ALL and were treated at
the Sainte-Justine UHC (SJUHC) in Montreal, Quebec,
but were otherwise healthy.
Sibling A, a 2 year old male, had a white blood cell
count (WBC) of 4.4 × 109/L, 14 and 75.5 % lympho-
blast cells in the blood and bone marrow respectively,
and a platelet count of 315.0 × 109/L. Cytogenetic ana-
lysis revealed hyperdiploidy with the following karyo-
type: 53,XY,+4,+6,+12,+15,+17,+18,+21, and fluorescent
in situ hybridization (FISH) identified a germline inver-
sion inv(2)(p11.2q13) that was also carried by the
mother. This recurrent pericentric inversion is stably
inherited without phenotypic or developmental conse-
quences and likely has no clinical relevance [15]. Sib A
was classified as standard risk and was enrolled on
Dana Farber Cancer Institute (DFCI) ALL Consortium
Protocol 95-01. He has been out of treatment for over
60 months with leukemia free-survival (LFS).
Sibling B, a 14 year old male, was diagnosed 3 years later
and was classified as high risk based on his age. He had a
WBC of 6.2 × 109/L, 18 and 93 % lymphoblast cells in the
blood and bone marrow respectively, and a platelet count
of 57.0 × 109/L. Cytogenetic analysis also revealed hyper-
diploidy: 54,XY,+X,+5,+8,+10,+14,+17,+18,+21, yet Sib B
did not carry his mother’s inv(2)(p11.2q13) inversion. Sib
B was enrolled on DFCI-ALL protocol 2000-01 for high-
risk patients; he has responded well to treatment and is
also over 60 months with LFS.
Whole exome sequence capture and sequencing
DNA was extracted from peripheral blood samples (ob-
tained after remission) from the sibship, and from both
parents using standard protocols as described previ-
ously [16]. Whole exomes were captured in solution
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with Agilent’s SureSelect Human All Exon 50Mb kits, and
sequenced on the Life Technologies SOLiD System (sibship
mean coverage =28.1X, parents mean coverage =19.4X).
Reads were aligned to the hg19 reference genome using
SOLiD LifeScope software (see Fig. 2 for complete sequen-
cing analysis workflow). PCR duplicates were removed
using Picard [17]. Base quality score recalibration was per-
formed using the Genome Analysis ToolKit (GATK) [18]
and QC Failure reads were removed. Cleaned BAM files
were used to create pileup files using SAMtools [19].
Variant calling and annotation
Single nucleotide variations (SNVs) and insertion and de-
letion (indels) were called from pileup files using SNooPer,
an in-house variant caller that is based on a machine
learning approach and developed to minimize false posi-
tive variant calling in low-depth sequencing data (manu-
script submitted and software available upon request).
Using this familial design, we were able to effectively
incorporate parental sequence information to remove
Mendelian inconsistencies, reduce false-positive sequen-
cing and alignment errors, and facilitate the identification
of candidate disease-predisposing variants shared by both
affected siblings. Variant frequencies were assessed using
1000 Genomes [20] and NHLBI GO Exome Sequencing
Project (ESP) [21] databases. ANNOVAR [22] was used
for non-synonymous SNV annotation. The effect of
non-synonymous variants on protein conformation and
function was assessed using Sift [23], Polyphen2 [24]
and functional analysis through hidden markov models
(Fathmm, version 2.3) [25]. Sift, Polyphen2 and Fathmm
consider a variant as putatively damaging when it presents
a score ≤0.05, ≥0.957 and < −1.5, respectively. SiPhy [26]
was used to detect bases under selection using multiple
alignment data from 29 mammal genomes; larger is the
score, more conserved is the site.
Results & discussion
The sibs were diagnosed with nonsyndromic childhood
ALL 3 years apart. We previously identified a rare PRDM9
allele segregating within the familly [11]. PRDM9 is a his-
tone H3 methyltransferase involved in crossing-over at re-
combination hotspots and Holliday junctions. To further
characterize the underlying inherited genetic contribution
to this childhood ALL family in an unbiased manner, we
performed whole exome sequencing of the siblings and
both parents. Though the family was nonsyndromic and
asymptomatic for FA, this recessive disorder is linked to
hematopoietic dysfunction, chromosomal instability and
increased susceptibility to childhood ALL. Based on the
observed concordant hyperdiploid phenotype of both sib-
lings, we postulated that inherited rare disadvantaging
DNA variants in leukemia predisposing pathways like the
FA pathway could affect overall genomic instability and, in
combination with the rare allelic form of PRDM9, favour
nondisjunction of chromosomes leading to increased risk
of hyperdiploid pre-B ALL within this family. Under a re-
cessive disease model, we interrogated our exome data and
identified shared non-synonymous mutations that were
either compound heterozygous or homozygous variant
Fig. 1 Family pedigree. The family is of self-reported Moroccan origin and consists of five siblings, including two non-twinned brothers diagnosed
with pre-B acute lymphoblastic leukemia (A and B) as well as two healthy females and one healthy male. Affected probands are represented by
the shaded squares; cousins with poly-malformation syndrome are represented by half-shaded circles. Sequenced individuals are identified by
an asterisk
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Fig 2 Whole-exome sequencing analysis workflow. Boxes represent the analysis/cleaning steps. Cylinders represent the variant filtering steps used
in the data reduction strategy to identify inherited rare mutations shared by both sibs
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(Table 1) and specifically screened genes associated with
the leukemia predisposing syndrome FA (FANCA, FANCB,
FANCC, FANCD1/BRCA2, FANCD2, FANCE, FANCF,
FANCG, FANCI, FANCJ, FANCL, FANCM, FANCN/
PALB2, FANCO/RAD51C, FANCP/SLX4, FANCQ/XPF
and FANCS/BRCA1). Among the identified variants, we
identified a combination of missense variants in the FA gene
FANCP/SLX4 (compound heterozygous at rs137976282 and
rs79842542), corroborating the assumption of FA pathway
destabilization (Fig. 2). A more thorough investigation of the
other FA pathway genes led then to the identification
of a rare heterozygous variant in FANCA (rs61753269)
that was also shared by the sibs. Although this variant
was heterozygous, restricting the analysis to extremely
rare variants allowed us to identify potentially deleteri-
ous non-synonymous variations in FA genes that could
be contributing to inherited susceptibility to ALL in the
sibs. For FANCP/SLX4, both parents transmitted a pu-
tatively damaging allele to their affected offspring who
were therefore compound heterozygous at rs137976282
(ESP and 1000 Genomes general population MAF <0.001)
and rs79842542 (MAF =0.059 and 0.071 in 1000 Genomes
and ESP general populations respectively). While two of
the three in silico algorithms predicted that the compound
heterozygous variants in FANCP/SLX4 were likely deleteri-
ous (Sift score =0 for both alleles and Polyphen2 score =1
and 0.964 for rs79842542 and rs137976282 respectively),
only Fathmm predicted rs61753269 in FANCA to be
damaging (Fathmm score = −1.78) (Table 1). Neverthe-
less, the high conservation score at FANCA rs61753269
(SiPhy =12.742), combined with its extreme rarity in
the population (MAF <0.001 in 1000 Genomes and
ESP), suggest that this variant is under strong func-
tional constraint and therefore could have a specific
role on protein conformation. Although not a Fanconi
anemia gene per se, our exome data also revealed a
rare non-synonymous homozygous variant in GEN1
(rs16981869, MAF =0.145394, ESP general population
homozygous frequency q2 = 0.025), that was predicted
to be deleterious by all three algorithms. GEN1 is a
member of the FANCP/SLX4 complex involved in
Holliday junction resolution [27], and in conjunction
with PRDM9 and the FA genes identified here, could
be contributing to genomic instability in the sibs. Our in-
house exome database of 369 individuals from our child-
hood ALL cohort (103 patient-mother-father trios and 60
patients) from the QcALL cohort [28] (whole exome se-
quencing performed on Life Technologies SOLiD System
or Illumina HiSeq 2500; data available upon request),
revealed a single heterozygote patient at both FANCP/
SLX4 positions, 0/369 variant allele carriers at FANCA
rs61753269 and 3/369 carriers of the homozygous allele
at GEN1 rs16981869 (one patient and two parents). Inter-
estingly, the only two other cases harbouring either both
variants in FANCP/SLX4 or the homozygous variant in
GEN1 were also diagnosed with hyperdiploid pre-B ALL,
concordant with the sibship. Overall, the sibs were the only
two individuals who carried this particularly rare combin-
ation of damaging alleles at FANCA rs61753269, FANCP/
SLX4 rs137976282, rs79842542 and GEN1 rs16981869.
Fanconi anemia is a recessive genetic disorder and most
frequent cause of inherited bone marrow failure. To date,
17 FA genes have been identified and mutations within
these genes have been shown to cause DNA repair defects
leading to genomic instability and aneuploidy, characteristic
of FA [29]. Given cumulative hematopoietic dysfunction
and excess chromosomal instability, FA patients are at
higher risk of developing hematopoietic malignancies in-
cluding leukemia [30]. Interestingly, the rare variants
FANCP/SLX4 rs137976282 and FANCA rs61753269 have
previously been identified in familial breast cancer cases
[31–34], however their pathological effects in cancer
predisposition remain unknown. FANCA, mutated in
over 60 % of FA cases, is an essential member of the
FA core complex involved in monoubiquitination of
the FANCI/D2 complex which in turn guides down-
stream activation of the DNA repair processes for
resolving DNA interstrand cross-links during replica-
tion [35]. Mono-allelic deletion of FANCA has been
suggested to promote genetic instabilities associated
with acute myeloid leukemia [36]. FANCP/SLX4 on the
other hand, is a downstream component of the FA path-
way that codes for a Holliday junction resolvase. It acts as
a docking platform for three structure-specific endonucle-
ases XPF–ERCC1, MUS81–EME1 and SLX1 [37]. Re-
cently identified as a FA gene, FANCP/SLX4 modulates
DNA repair and cellular responses to replication fork fail-
ure [38]. GEN1 codes for an endonuclease, and is a mem-
ber of the FANCP/SLX4 complex [27] shown to play a
role in the maintenance of centrosome integrity [39].
Along with PRDM9, GEN1 and the FANCP/SLX4 com-
plex are involved in the definition of Holliday junction
branch migration boundaries and the cleavage of static
and migrating Holliday junctions [12, 27, 37]. Efficient
DNA damage repair and simultaneous regulation of cell
cycle progression is critical for genomic stability. Interest-
ingly, a rare recessive homozygous variant in GEN1 has
been associated with bilateral breast cancer [40] and the
depletion of GEN1 or FANCP/SLX4 in Bloom’s syndrome
cells results in defects in chromosome condensation and
severe chromosome abnormalities, such as nondisjunction
of sister chromatids and abnormal mitosis leading to an-
euploidy [41, 42], highlighting their important role in
maintaining genome stability. Thus, mutated FANCP/
SLX4 and GEN1, in combination with the rare allele of
PRDM9 also segregating within this family, could alter
Holliday junction resolution leading to nondisjunction of
chromosomes and segregation defects.
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Table 1 Non-synonymous homozygous variants and compound heterozygous shared by both childhood pre-B ALL siblings
Gene SNP ID Chr Position Ref Sibs Father Mother AA change 1000g MAF ESP MAF/q2 Sift Polyphen2 Fathmm SiPhy
Compound heterozygous FANCP/SLX4 rs79842542 16 3656625 GG AG AG GG R204C 0.06 0.071264/- 0 1 3.49 12.9
rs137976282 16 3658545 CC AC CC AC G141W 0 0.00077/- 0 0.96 5.2 7.27
CEP55 rs75139274 10 95278683 GG AG AG GG R348K 0.03 0.074581/- 0.19 0.21 2.05 11.44
rs2293277 10 95279506 AA TA AA TA H378L 0.56 0.610257/- 0.13 0.48 2.21 14.69
DNAH2 rs140035206 17 7673930 AA GA GA AA Y1385C 0 0.004075/- 0 1 −0.15 15.1
rs79350244 17 7734114 AA CA AA CA I4023L 0.01 0.021913/- 1 0.52 3.81 15.2
rs117465420 17 7734476 AA TA AA TA L4062F 0.01 0.021759/- 0.02 0.41 3.06 8.22
rs78354379 17 7736480 TT AT AT TT V4357D 0.05 0.008073/- 0.03 0.99 2.95 12.12
PDE4DIP rs1778120 1 144879090 CC CT CT TT K1410E - 0.124712/- 0.11 1 4.64 11.54
rs1698683 1 144916676 CC TC CC TC W626* - 0.321203/- 0.16 NA 3.81 18.03
Homozygous GEN1 rs16981869 2 17946243 AA GG GA GA N143S 0.13 0.145394/0.025 0.03 0.81 −0.45 8.03
B3GALTL rs1041073 13 31891746 GG AA AG AG E370K 0.67 0.65539/0.442 0.28 0.96 −1.92 7.09
CA9 rs2071676 9 35674053 AA AA AG AG V33L 0.32 0.269107/0.560 0 0.82 −0.66 8.01
CHIT1 rs2297950 1 203194186 CC TT TC TC G102S 0.29 0.285253/0.065 0 1 3.81 7.76
CHRNB1 rs17856697 17 7348625 AA GG GA GA E32G 0.12 0.25585/0.052 0.08 0.77 −1.16 8.74
ERBB2 rs1058808 17 37884037 CC GG GC GC P1170A 0.45 0.513532/0.278 0.03 0.95 −0.81 18.01
ZNF207 rs3795244 17 30692396 GG TT TG TG A240S 0.05 0.045748/0.001 0.41 0.75 0.85 20.21
(−) represents missing or not relevant information. (*) represents stop codons. For these genes, either or both parents transmitted a putatively damaging allele to their affected offspring, who were therefore
compound heterozygous or homozygous, respectively. Genotype calls are provided for each sample (Sibs, Father and Mother) along with corresponding amino acid (AA) changes. Minor allele frequencies (MAF) were
derived from the 1000 Genomes (general population, updated in October 2014) and the NHLBI GO Exome Sequencing Project (general population, ESP6500). The frequencies of homozygous variants (q2) were
obtained from ESP6500 and were presented when relevant. The putative effect of these substitutions on the protein function was assessed in silico using Sift (≤0.05) [23], Polyphen2 (≥0.957) [24] and Fathmm (<−1.5)











While autosomal recessive FA patients are known to
present with malformations [43], it has been reported that
heterozygous carriers of a FA gene may be predisposed to
some of the same congenital malformations or develop-
mental abnormalities that are common among homozy-
gotes [44]. Although the sibs had no apparent physical
abnormalities, family history revealed a consanguineous
marriage on the paternal side (Fig. 1) resulting in multiple
miscarriages and polymalformation syndrome in surviving
offspring. Given that both rare FANCP/SLX4 rs137976282
and FANCA rs61753269 variants were paternally inherited
we could hypothesize an underlying recessive disorder af-
fecting the FA pathway; however this remains highly
speculative without further genotype information on the
extended family. Overall, these data support a functional
role for the rare variants identified in FANCA, FANCP/
SLX4 and GEN1 in disrupting the FA pathway and Holliday
junction resolution, and as a result, they could lead to gen-
omic instability and hematopoietic dysfunction, and in-
creased risk of ALL within this family. However functional
assays are required to confirm these observations.
Despite the fact that both siblings were asymptomatic
and were not diagnosed with an ALL-linked genetic dis-
order, the possibility of an underlying FA condition exists
and an undiagnosed disorder, although rare, cannot be ex-
cluded. One may argue that pure, nonsyndromic ALL
families are unlikely and that genetic interrogation of such
families will ultimately reveal underlying inherited disor-
ders associated with increased risk of ALL. Indeed, our re-
sults show that the study of familial or inherited forms of
ALL can further our understanding of the genetic causes
underlying more common, sporadic forms and shed light
on otherwise asymptomatic genetic syndromes.
Finally, though our rare variant analysis strongly suggests
FANCP/SLX4 and FANCA as the most likely candidates,
we cannot exclude the possibility that additional inherited
genetic variants, rare or common, outside of the FA path-
way could contribute to ALL onset within the family. For
example, we identified common non-synonymous variants
in PDE4DIP and CEP55 (Table 1). Though these centroso-
mal proteins have been involved in myeloproliferative dis-
order [45] and carcinogenesis [46] and could promote
abnormal cell division and hyperdiploidy, as evidenced re-
cently by Paulsson et al. [47], the identified variants had
high MAFs and were predicted to have benign effects on
protein function, making them unlikely candidates here.
Furthermore, the sibs carry common ALL susceptibility
alleles at known GWAS loci [3–6, 28] (Table 2), that
under an additive effects model could lead up to a 2- to
10-fold increase in risk [9]. Given the male-specific in-
heritance, we also looked for shared deleterious vari-
ants on the X chromosome but found no evidence of
X-linked genes contributing to ALL in this family. The
exomes of the siblings were also screened for shared de
novo mutations that could result from gonadal mosaicism.
Putative de novo events were defined as private mutations
shared by both siblings, and therefore unknown in public
databases, and showing no evidence of heritability from
either parent, i.e. no reads supporting the variation in the
parental exomes considering a minimum coverage of 8X
at the given position in the exome sequencing data. Al-
though no candidate de novo mutation fitting our criteria
was identified, the limited coverage of parental exomes
may have hindered this analysis. The investigation of more
complex genetic models including gene-gene and eventu-
ally gene-environment interactions could also reveal add-
itional ALL risk factors.
Conclusions
Nonsyndromic families with multiple non-twinned siblings
diagnosed with childhood ALL are extremely rare but rep-
resent an interesting model to characterize the influence of
inherited genetic burden on disease onset. This unique set-
ting can also facilitate the identification of novel genes/
pathways involved in driving the leukemic process and fur-
ther our understanding of the mechanisms involved in
childhood pre-B ALL and its subtypes. Here, we used
next-generation sequencing technologies to sequence
the whole-exomes of a childhood ALL family consisting
of mother, father and two male affected sibs. Both
brothers were diagnosed with pre-B hyperdiploid childhood
ALL and their similar clinical and molecular characteristics
suggested shared etiologic factors. Though functional valid-
ation studies are required to substantiate the role of these
Table 2 Childhood ALL susceptibility loci genotyped in siblings
A and B
Gene SNP ID Ref A B
ARID5B rs7073837 CC - AA
rs10994982 GG GA AA
rs10740055 AA - CC
rs10821936 TT - CC
rs7089424 TT - GG
CEBPE rs2239633 CC CT TT
DDC rs7809758 AA AG AG
rs880028 TT TC TC
rs3779084 TT TC TC
rs2242041 CC GG CG
IKZF1 rs6964823 GG GA GA
rs11978267 AA - AG
rs4132601 TT - TG
rs6944602 GG GG GG
OR2C3 rs1881797 TT TT -
CDKN2A rs36228834 TT TT TT
(−) represents missing information
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variants in hyperdiploid pre-B childhood ALL, our data
suggest that concomitant inheritance of rare variants in
FA genes FANCA, FANCP/SLX4, in combination with
rare mutations in the endonuclease GEN1 and the meiotic
recombination gene PRDM9, could lead to increased
DNA damage and genomic instability, and thus contribute
to hyperdiploid leukemia predisposition.
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